Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 48Terminated 9Recruiting 3Withdrawn 2Active not recruiting 2Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 8Other hematologic neoplasm 7Lymphoid 4Sarcoma 3Plasma cell 3Genitourinary 2Gynecologic 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Neoplasms 23Venous Thromboembolism 20Febrile Neutropenia 20Anemia 20Thrombocytopenia 15Myelodysplastic Syndromes 14Leukemia, Myeloid, Acute 14Lymphoma 12Leukemia 12Anemia, Refractory, with Excess of Blasts 10Anemia, Aplastic 10Colorectal Neoplasms 9Breast Neoplasms 8Anemia, Iron-Deficiency 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Anemia, Sickle Cell 7Neutropenia 6Multiple Myeloma 6Ovarian Neoplasms 5Neoplasms, Plasma Cell 5Lymphoma, Follicular 5Hematologic Neoplasms 5Fanconi Anemia, Complementation Group D1 5Hemophilia A 4Chemotherapy-induced Thrombocytopenia 4Stroke 3Pulmonary Disease, Chronic Obstructive 3Parkinson Disease 3Osteoporosis 3Multiple Sclerosis 3

Interventions

Decitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Myelodysplastic-Myeloproliferative Diseases × Classical hematology × Clear all
NCT00043134 2010-04-13

Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 3 Unknown
220 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡